- Home
- GIPR vs ACXP Comparison
GIPR vs ACXP Comparison
Compare GIPR & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIPR
- ACXP
- Stock Information
- Founded
- GIPR 2015
- ACXP 2017
- Country
- GIPR United States
- ACXP United States
- Employees
- GIPR N/A
- ACXP N/A
- Industry
- GIPR Real Estate Investment Trusts
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- GIPR Real Estate
- ACXP Health Care
- Exchange
- GIPR Nasdaq
- ACXP Nasdaq
- Market Cap
- GIPR 8.8M
- ACXP 8.4M
- IPO Year
- GIPR 2021
- ACXP 2021
- Fundamental
- Price
- GIPR $1.46
- ACXP $0.35
- Analyst Decision
- GIPR Hold
- ACXP Strong Buy
- Analyst Count
- GIPR 1
- ACXP 2
- Target Price
- GIPR N/A
- ACXP $10.00
- AVG Volume (30 Days)
- GIPR 19.7K
- ACXP 233.4K
- Earning Date
- GIPR 05-15-2025
- ACXP 05-13-2025
- Dividend Yield
- GIPR 2.63%
- ACXP N/A
- EPS Growth
- GIPR N/A
- ACXP N/A
- EPS
- GIPR N/A
- ACXP N/A
- Revenue
- GIPR $9,711,058.00
- ACXP N/A
- Revenue This Year
- GIPR N/A
- ACXP N/A
- Revenue Next Year
- GIPR N/A
- ACXP N/A
- P/E Ratio
- GIPR N/A
- ACXP N/A
- Revenue Growth
- GIPR 11.25
- ACXP N/A
- 52 Week Low
- GIPR $1.43
- ACXP $0.30
- 52 Week High
- GIPR $4.55
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- GIPR 35.32
- ACXP 37.87
- Support Level
- GIPR $1.46
- ACXP $0.34
- Resistance Level
- GIPR $1.66
- ACXP $0.36
- Average True Range (ATR)
- GIPR 0.12
- ACXP 0.02
- MACD
- GIPR -0.02
- ACXP -0.00
- Stochastic Oscillator
- GIPR 0.00
- ACXP 5.19
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.